China Biotech Services Holdings (HKSE:08037) Debt-to-Equity : 0.22 (As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

What is China Biotech Services Holdings Debt-to-Equity?

China Biotech Services Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$94.7 Mil. China Biotech Services Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$5.7 Mil. China Biotech Services Holdings's Total Stockholders Equity for the quarter that ended in Dec. 2023 was HK$462.8 Mil. China Biotech Services Holdings's debt to equity for the quarter that ended in Dec. 2023 was 0.22.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for China Biotech Services Holdings's Debt-to-Equity or its related term are showing as below:

HKSE:08037' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.13 Max: 0.31
Current: 0.22

During the past 13 years, the highest Debt-to-Equity Ratio of China Biotech Services Holdings was 0.31. The lowest was 0.01. And the median was 0.13.

HKSE:08037's Debt-to-Equity is ranked better than
50.78% of 193 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.23 vs HKSE:08037: 0.22

China Biotech Services Holdings Debt-to-Equity Historical Data

The historical data trend for China Biotech Services Holdings's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Biotech Services Holdings Debt-to-Equity Chart

China Biotech Services Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.15

0.31

0.17

0.14

0.22

China Biotech Services Holdings Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.14	N/A	0.13	N/A	0.22

Competitive Comparison of China Biotech Services Holdings's Debt-to-Equity

For the Diagnostics & Research subindustry, China Biotech Services Holdings's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

China Biotech Services Holdings's Debt-to-Equity Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, China Biotech Services Holdings's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where China Biotech Services Holdings's Debt-to-Equity falls into.

China Biotech Services Holdings Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

China Biotech Services Holdings's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(94.669	+	5.727)	/	462.754
	=	0.22

China Biotech Services Holdings's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(94.669	+	5.727)	/	462.754
	=	0.22

China Biotech Services Holdings (HKSE:08037) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

China Biotech Services Holdings Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of China Biotech Services Holdings's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

China Biotech Services Holdings (HKSE:08037) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » China Biotech Services Holdings Ltd (HKSE:08037) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

255-257 Gloucester Roaad, Suites 1904-05A, 19th Floor, Sino Plaza, Causeway Bay, Hong Kong, HKG

Website

http://www.cbshhk.com

China Biotech Services Holdings Ltd is an investment holding company. It operates through six segments: Pharmaceutical Products, Medical and Health-Related Services, Immunotherapy, Securities, Insurance brokerage, BNCT and Others. It derives prime revenue from the Medical and health related services segment which involves the provision of medical laboratory testing and health check services. The group has a business presence in Hong Kong and the PRC, of which key revenue is generated from Hong Kong.

Executives

Liu Xiaolin	2101 Beneficial owner
Genius Earn Limited	2201 Interest of corporation controlled by you
Genius Lead Limited	2101 Beneficial owner
Guoyuan International Holdings Limited	2201 Interest of corporation controlled by you
Guoyuan Securities Co., Ltd.	2201 Interest of corporation controlled by you
Guoyuan Securities Investment (hong Kong) Limited	2101 Beneficial owner
Richlane Ventures Limited	2101 Beneficial owner
Ko Chun Shun, Johnson	2201 Interest of corporation controlled by you

China Biotech Services Holdings (HKSE:08037) Headlines

No Headlines